Glioblastoma (GBM) is known as a highly aggressive and malignant form of brain cancer. Despite advances in understanding the genetic and molecular basis of glioblastoma, it has a poor prognosis with a median survival rate of 9 months. The complex interplay between malignant cells and the surrounding tumor microenvironment (TME) plays a pivotal role in tumor progression and treatment respons…